Mobile

The purpose of this study is to find out more about romosozumab in women with postmenopausal osteoporosis. This study will see if romosozumab, given in two different forms, increases bone mineral den...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-000434-35

The purpose of this study is to find out more about romosozumab in women with postmenopausal osteoporosis. This study will see if romosozumab, given in two different forms, increases bone mineral density and whether it causes any side effects. To do this, romosozumab at one concentration and in one type of syringe will be compared to romosozumab at another concentration and in another type of syringe

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab administered every month (QM) using a 90 mg/mL concentration compared with 210 mg romosozumab QM using a 70 mg/mL concentration on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy x-ray absorptiometry (DXA) in postmenopausal women with osteoporosis

Critère d'inclusion

  • Postmenopausal osteoporosis

Liens